Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19. This can be found at the link,’Antib…
-
Noosa News14 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
General14 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News18 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
Business16 hours ago10 ASX shares to buy after the market selloff